ay-za-THYE-oh-preen
Therapeutic Classification: Immunosuppressant agents
Pharmacologic Classification: purine antagonists
REMS
Absorption: Readily absorbed after oral administration. IV administration results in complete bioavailability.
Distribution: Unknown
Half-Life: 3 hr.
Contraindicated in:
Use Cautiously in:
CV: Raynaud phenomenon
Derm: alopecia, rash
EENT: retinopathy
GI: anorexia, hepatotoxicity, nausea, vomiting, diarrhea, mucositis, pancreatitis
Hemat: anemia, leukopenia, pancytopenia, thrombocytopenia
MS: arthralgia
Neuro: PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)
Resp: pulmonary edema
Misc: chills, fever, MALIGNANCY (INCLUDING POST-TRANSPLANT LYMPHOMA, HSTCL, AND SKIN CANCER), SERUM SICKNESS
Drug-drug:
Drug-Natural Products:
Renal Allograft Rejection Prevention
Rheumatoid Arthritis
Inflammatory Bowel Disease (Crohn Disease or Ulcerative Colitis) (unlabeled use)
Monitor for signs of malignancy (splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, and weight loss).
Lab Test Considerations:
IV Administration:
Inform patient of ↑ risk of malignancy. For patients with ↑ risk for skin cancer, exposure to sunlight and ultraviolet light should be limited by wearing protective clothing and using a sunscreen with a high protection factor.
NDC Code